Riskpilot← Back to searchSign inGet full accessMamocon AB
ABActiveOrg 5568594575Gravörgatan 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20113 employees
Revenue 2024
SEK 37,6M
+8% vs 2023
EBITDA margin
18.7%
+17% vs 2023
Equity ratio
56.1%
Financial strength
Net profit 2024
SEK 4,2M
+20% vs 2023
| Revenue | SEK 37,6M | +8% |
| EBITDA | SEK 7M | +17% |
| Net profit | SEK 4,2M | +20% |
| Total assets | SEK 18,9M | +33% |
| Equity | SEK 10,6M | +43% |
| Employees | 3 | — |
Legal name
Mamocon AB
Org number
5568594575
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 juli 2011
Share capital
SEK 50 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva konsultverksamhet med farmaceutisk inriktning, bedriva handel med medicintekniska produkter och läkemedel och därmed förenlig verksamhet.
Address
Gravörgatan 1
Email
martin@mamocon.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 11 611 | 12 418 | 22 140 | 34 893 | 37 590 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 966 | 2 332 | 4 589 | 6 025 | 7 043 |
| Depreciation & amort. | −0 | −0 | −0 | −95 | −95 |
| EBIT | 966 | 2 332 | 4 589 | 5 930 | 6 948 |
| Net financials | −45 | −29 | −24 | 7 | 32 |
| Profit before tax | 691 | 1 728 | 3 425 | 4 410 | 5 308 |
| Tax | −148 | −357 | −707 | −916 | −1 114 |
| Net profit | 543 | 1 371 | 2 718 | 3 494 | 4 194 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 948 | 5 393 | 10 883 | 14 123 | 18 854 |
| Equity | 799 | 2 170 | 4 889 | 7 382 | 10 576 |
| Long-term debt | 442 | 375 | 375 | 0 | 0 |
| Short-term debt | 1 396 | 1 961 | 3 594 | 3 187 | 3 053 |
| Total debt | 1 838 | 2 336 | 3 969 | 3 187 | 3 053 |
EBITDA margin
18.7%
This company
15.8%
Market median
+18% vs market
20202024
Equity ratio
56.1%
This company
38.2%
Market median
+47% vs market
20202024
Return on equity
39.7%
This company
18.4%
Market median
+116% vs market
20202024
Net profit margin
11.2%
This company
8.1%
Market median
+38% vs market
20202024
Asset turnover
1.99×
This company
1.12×
Market median
+78% vs market
20202024
Debt / equity
0.78×
This company
0.62×
Market median
+26% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PO Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mamocon AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Olow Rosenqvist | Chief Auditor | 0 companies |
| Jan Martin Molin | Board of Directors | 0 companies |
| I Helena M Molin Kronberg | Deputy Board Member | 0 companies |